Two cardiometabolic-related news items have been observed: Novo Nordisk announced its full-year sales and operating profit outlook has been raised for 2023 (view press release); and Sana Biotechnology announced the appointment of Douglas E. Williams, as President of R&D, and Gary Meininger, MD, as CMO, of its R&D organization (view press release). Separately, Sana announced the publication of pre-clinical data for its hypoimmune pancreatic islet cells in Science and Translational Medicine (view press release). Below, FENIX provides highlights and insights into the respective news items.